Ostatní
Návod 
Emergent BioSolutions Inc.
EBS
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
0.6B
Obrat
1B
Zisk
0B
Aktiva
1B
Dluh
1B
ROE
13%
ROA
5%
PE
9
PS
1
Cena 1R
4-14
⌀ Cena
8.36
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
02-03-2026
Poslední dividenda
Profil
Emergent BioSolutions Inc., společnost zabývající se vědami o živé přírodě, se zaměřuje na poskytování řešení připravenosti a reakce, která řeší náhodné, záměrné a přirozeně se vyskytující ohrožení veřejného zdraví (PHT) ve Spojených státech. Výrobky společnosti se zabývají PHT, které zahrnují chemické, biologické, radiologické, jaderné a výbušniny; nově vznikající infekční choroby; cestovní zdravotní stav; a vznikající zdravotní krize a akutní/urgentní péče. Nabízí BioThrax, antraxovou vakcínu; ACAM2000, vakcínu proti neštovicím; Botulismus Antitoxin Heptavalent k léčbě botuloidní choroby; vakcínu proti intravenóznímu imunoglobulinu, která řeší komplikace způsobené vakcínou proti neštovicím; raxibacumab k léčbě a profylaxi inhalačního antraxu; antrasil k inhalačnímu antraxu; reaktivní kožní dekontaminační lokační soupravy; a Trobigard, kandidát na autoinjektory kombinovaných lékových zařízení; a Trobigard produktový kandidát Společnost také poskytuje NARCAN, nosní sprej pro urgentní léčbu známého nebo předpokládaného předávkování opiáty; Vivotif, perorální vakcínu proti břišní tyfové horečce; a Vaxchora, perorální vakcínu pro jednorázovou léčbu cholery. Dále vyvíjí AP003, Naloxonový vícedávkový nosní sprej; AP007, injekci Nalmefenu s prodlouženým uvolňováním pro léčbu poruch souvisejících s užíváním opiátů; AV7909, antraxovou vakcínu; CGRD-001, autoinjektor pralidoxim chloridu/atropinu; CHIKV VLP, vakcínu proti viru chikungunya VLP; COVID-HIG pro léčbu SARS-CoV2; EGRD-001, autoinjektor diazepamu; SIAN, antidotum pro počáteční léčbu akutní otravy a UniFlu, univerzální vakcíny proti chřipce. Dále společnost poskytuje služby v oblasti vývoje smluv a výroby zahrnující výrobu léčiv a produktů, balení, jakož i přenos technologií, procesní a analytický vývoj. Společnost byla založena v roce 1998 a sídlí v Gaithersburgu v Marylandu.
Sektor
Healthcare
Odvětví
Drug Manufacturers - Specialty & Generic
Počet zaměstnanců
900
Založení
2006-11-15
Podobné společnosti
$ 6.46
- $ 0.08
$ 1.85
+ $ 0.07
$ 2.79
+ $ 0.13
$ 34.23
- $ 0.96
$ 5.91
+ $ 0.28
$ 10.80
+ $ 0.24
$ 5.59
+ $ 0.14
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 742.9 | 742.9 | 1,043.6 | 1,049.3 | 1,120.9 | 1,792.7 | 1,555.4 | 1,106.0 | 782.4 | 560.9 | 488.8 | 522.8 | 450.1 | 312.7 | 281.9 | 273.4 | 286.2 | |
| Cost of Revenues | 392.3 | 392.3 | 668.2 | 705.4 | 693.7 | 757.5 | 524.0 | 433.5 | 322.3 | 195.7 | 131.3 | 124.3 | 118.4 | 62.1 | 46.1 | 42.2 | 47.1 | |
| Gross Profit | 350.6 | 350.6 | 375.4 | 343.9 | 427.2 | 1,035.2 | 1,031.4 | 672.5 | 460.1 | 365.2 | 357.5 | 398.5 | 331.7 | 250.6 | 235.8 | 231.2 | 239.1 |
| Revenue | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 148.7 | 231.1 | 140.9 | 222.2 | 194.7 | 293.8 | 254.7 | 300.4 | 276.6 | 270.5 | |
| Cost of Revenues | 117.6 | 91.7 | 80.2 | 102.8 | 58.2 | 129.6 | 320.2 | 159.6 | 201.8 | 176.8 | |
| Gross Profit | 31.1 | 139.4 | 60.7 | 119.4 | 136.5 | 164.2 | -65.5 | 140.8 | 74.8 | 93.7 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 111.4 | 193.0 | 234.0 | 234.5 | 226.2 | 142.8 | 97.4 | 108.3 | 154.0 | 150.8 | 119.9 | 120.2 | 124.8 | 89.3 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 368.4 | 340.3 | 348.4 | 303.3 | 273.5 | 202.5 | 143.5 | 143.7 | 148.5 | 122.8 | 87.9 | 76.0 | 74.3 | 76.2 | |
| Depreciation & Amortization | 94.7 | 98.3 | 105.6 | 125.1 | 131.6 | 161.8 | 119.2 | 112.4 | 25.0 | 42.6 | 38.2 | 35.3 | 32.5 | 19.0 | 11.2 | 9.4 | 6.0 | |
| Total Operating Expenses | 240.4 | 240.4 | 484.1 | 1,044.0 | 593.2 | 640.9 | 597.6 | 558.4 | 370.3 | 240.9 | 252.0 | 302.5 | 273.7 | 207.8 | 196.2 | 199.1 | 165.5 | |
| Operating Income | 110.2 | 110.2 | -108.7 | -726.4 | -166.0 | 352.6 | 433.8 | 114.1 | 89.8 | 124.3 | 105.5 | 96.0 | 58.1 | 42.8 | 30.0 | 32.1 | 73.6 |
| Operating Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 29.2 | 15.3 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 87.5 | 86.0 | ||
| Depreciation & Amortization | 23.5 | 23.4 | 23.0 | 24.8 | 25.3 | 25.7 | 27.6 | 27.0 | 30.5 | 29.1 | ||
| Total Operating Expenses | 48.9 | 62.9 | 59.1 | 69.5 | 146.0 | 99.7 | 138.0 | 101.0 | 116.7 | 117.6 | ||
| Operating Income | -17.8 | 76.5 | 1.6 | 49.9 | -9.5 | 64.5 | -203.5 | 39.8 | -41.9 | -242.1 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.8 | 1.1 | 0.6 | 0.3 | 0.1 | 0.1 | 0.1 | 0.8 | |
| Interest Expense | 148.5 | 59.3 | 71.0 | 87.9 | 37.3 | 34.5 | 31.3 | 38.4 | 9.9 | 6.6 | 7.6 | 6.5 | 8.2 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Expense | -27.4 | -27.4 | -34.2 | -4.8 | -55.7 | -38.2 | -26.6 | -36.7 | 1.6 | -0.8 | 0.3 | -0.3 | 2.9 | 0.4 | -7.6 | -0.3 | -1.0 | |
| IBT | 82.8 | 82.8 | -142.9 | -731.2 | -221.7 | 314.4 | 407.2 | 77.4 | 81.5 | 118.6 | 99.2 | 89.8 | 53.1 | 43.4 | 32.1 | 31.9 | 73.4 | |
| Income Tax Expense | 30.2 | 30.2 | 47.7 | 29.3 | 2.1 | 83.5 | 102.1 | 22.9 | 18.8 | 36.0 | 36.7 | 26.9 | 16.3 | 13.1 | 13.9 | 15.8 | 26.2 | |
| Net Income | 52.6 | 52.6 | -190.6 | -760.5 | -223.8 | 230.9 | 305.1 | 54.5 | 62.7 | 82.6 | 51.8 | 62.9 | 36.7 | 31.1 | 23.5 | 23.0 | 51.7 |
| Net Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 | 0.0 | ||
| Interest Expense | 103.9 | 15.2 | 14.7 | 14.7 | 14.8 | 8.3 | 23.6 | 24.3 | 22.2 | 19.7 | ||
| Other Expense | -32.9 | -18.9 | -18.4 | 42.8 | -18.1 | 77.9 | -66.3 | -27.7 | -12.6 | -23.8 | ||
| IBT | -50.7 | 57.6 | -16.8 | 92.7 | -27.6 | 142.4 | -269.8 | 12.1 | -54.5 | -265.9 | ||
| Income Tax Expense | 3.9 | 6.4 | -4.8 | 24.7 | 3.7 | 27.6 | 13.3 | 3.1 | -5.0 | 16.3 | ||
| Net Income | -54.6 | 51.2 | -12.0 | 68.0 | -31.3 | 114.8 | -283.1 | 9.0 | -49.5 | -265.9 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $-14.85 | $-4.47 | $4.32 | $5.79 | $1.06 | $1.25 | $1.98 | $1.29 | $1.63 | $0.98 | $0.86 | $0.65 | $0.65 | $1.63 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $-14.85 | $-4.47 | $4.27 | $5.67 | $1.04 | $1.22 | $1.71 | $1.13 | $1.41 | $0.88 | $0.85 | $0.65 | $0.64 | $1.59 | |
| Shares Outstanding | 53.5 | 53.5 | 53.0 | 51.2 | 50.1 | 53.5 | 52.7 | 51.5 | 50.1 | 41.8 | 40.2 | 38.6 | 37.3 | 36.2 | 36.1 | 35.7 | 31.8 | |
| Diluted Shares Outstanding | 56.7 | 56.7 | 53.0 | 51.2 | 50.1 | 54.1 | 53.8 | 52.4 | 51.4 | 50.3 | 49.3 | 47.3 | 45.8 | 36.7 | 36.4 | 36.2 | 32.5 |
| Per Share Data | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.95 | $-5.13 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.95 | $-5.13 | ||
| Shares Outstanding | 53.5 | 53.2 | 54.2 | 54.4 | 54.2 | 53.1 | 52.6 | 52.2 | 51.9 | 51.8 | ||
| Diluted Shares Outstanding | 56.7 | 56.5 | 54.2 | 57.3 | 54.2 | 55.6 | 52.6 | 52.2 | 51.9 | 51.8 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 71.0 | 99.5 | 111.7 | 642.6 | 576.1 | 621.3 | 167.8 | 112.2 | 178.3 | 271.5 | 312.8 | 280.5 | 179.3 | 141.7 | 143.9 | 169.0 | |
| Short Term Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.0 | 2.0 | |
| Total Cash & ST Investments | 71.0 | 99.5 | 111.7 | 642.6 | 576.1 | 621.3 | 167.8 | 112.2 | 178.3 | 271.5 | 312.8 | 280.5 | 179.3 | 141.7 | 145.9 | 171.0 | |
| Accounts Receivable | 196.3 | 154.5 | 191.0 | 158.4 | 274.7 | 230.9 | 275.3 | 271.1 | 146.1 | 148.5 | 127.3 | 60.2 | 66.2 | 96.0 | 83.7 | 48.1 | |
| Inventory | 317.5 | 311.7 | 328.9 | 351.8 | 350.8 | 307.0 | 222.5 | 205.8 | 142.8 | 74.0 | 76.9 | 65.7 | 14.6 | 15.2 | 14.7 | 12.7 | |
| Other Current Assets | 69.7 | 33.0 | 47.9 | 57.9 | 70.5 | 36.7 | 20.6 | 31.7 | 18.2 | 16.2 | 21.5 | 25.8 | 12.9 | 10.5 | 10.2 | 11.7 | |
| Total Current Assets | 654.5 | 598.7 | 679.5 | 1,210.7 | 1,272.1 | 1,195.9 | 686.2 | 620.8 | 485.4 | 510.2 | 538.6 | 432.2 | 273.1 | 263.3 | 254.4 | 243.5 |
| Current Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 245.5 | 271.0 | 149.1 | 105.6 | 149.9 | 69.7 | 79.0 | 111.7 | 87.8 | 88.6 | |
| Short Term Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Cash & ST Investments | 245.5 | 271.0 | 149.1 | 105.6 | 149.9 | 69.7 | 79.0 | 111.7 | 87.8 | 88.6 | |
| Accounts Receivable | 149.5 | 79.8 | 203.7 | 154.5 | 121.3 | 196.3 | 233.5 | 191.0 | 216.5 | 290.1 | |
| Inventory | 356.3 | 338.6 | 314.0 | 311.7 | 322.7 | 317.5 | 333.4 | 328.9 | 354.1 | 354.3 | |
| Other Current Assets | 35.6 | 30.1 | 40.0 | 26.9 | 67.5 | 71.0 | 36.5 | 47.9 | 62.4 | 44.7 | |
| Total Current Assets | 786.9 | 719.5 | 706.8 | 598.7 | 661.4 | 654.5 | 682.4 | 679.5 | 354.1 | 777.7 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 319.9 | 270.6 | 399.0 | 817.6 | 800.1 | 644.1 | 542.3 | 510.2 | 407.2 | 376.4 | 331.9 | 314.0 | 264.2 | 241.8 | 209.0 | 152.7 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 218.2 | 224.9 | 266.7 | 268.6 | 259.7 | 49.1 | 41.0 | 54.9 | 42.0 | 14.0 | 5.5 | 5.5 | 5.0 | |
| Intangible Assets | 534.1 | 501.5 | 566.6 | 728.8 | 604.6 | 663.1 | 741.9 | 811.6 | 119.6 | 33.9 | 99.9 | 136.1 | 71.9 | 41.8 | 51.4 | 51.4 | |
| Long-Term Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Long-Term Assets | 5.0 | 18.9 | 178.1 | 191.3 | 57.3 | 113.4 | 76.9 | 13.7 | 6.0 | 2.5 | 7.1 | 8.2 | 3.4 | 0.7 | 12.6 | 13.9 | |
| Total Long-Term Assets | 859.0 | 791.0 | 1,143.7 | 1,955.9 | 1,686.9 | 1,687.3 | 1,643.1 | 1,608.6 | 584.8 | 459.9 | 505.0 | 513.1 | 353.5 | 300.9 | 292.4 | 256.8 | |
| Total Assets | 1,513.5 | 1,389.7 | 1,823.2 | 3,166.6 | 2,959.0 | 2,883.2 | 2,329.3 | 2,229.4 | 1,070.2 | 970.1 | 1,043.6 | 945.3 | 626.6 | 564.2 | 546.9 | 500.3 |
| Long-Term Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 209.8 | 223.8 | 221.0 | 282.3 | 290.5 | 319.9 | 394.7 | 399.0 | 395.4 | 395.5 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 218.2 | |
| Intangible Assets | 452.7 | 469.0 | 485.2 | 501.5 | 517.8 | 534.1 | 550.4 | 566.6 | 582.8 | 592.8 | |
| Long-Term Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Long-Term Assets | 11.6 | 4.8 | 13.1 | 7.2 | 8.1 | 5.0 | 176.1 | 178.1 | 194.1 | 194.6 | |
| Total Long-Term Assets | 674.1 | 697.6 | 719.3 | 798.2 | 816.4 | 859.0 | 1,121.2 | 1,155.4 | 1,172.3 | 1,401.1 | |
| Total Assets | 1,461.0 | 1,417.1 | 1,426.1 | 1,396.9 | 1,477.8 | 1,513.5 | 1,803.6 | 1,834.9 | 1,893.1 | 2,178.8 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 95.9 | 60.9 | 112.2 | 103.5 | 128.9 | 136.1 | 94.8 | 80.7 | 41.8 | 34.6 | 46.0 | 40.9 | 27.5 | 31.3 | 40.5 | 25.4 | |
| Short-Term Debt | 418.3 | 2.7 | 413.7 | 957.3 | 31.6 | 33.8 | 12.9 | 10.1 | 42.7 | 20.0 | 43.2 | 40.2 | 26.0 | 4.5 | 5.4 | 17.2 | |
| Other Current Liabilities | 99.3 | 98.8 | 125.4 | 169.1 | 72.9 | 83.1 | 6.7 | 99.0 | 2.4 | 44.2 | 2.6 | 6.5 | 1.3 | 24.3 | 23.8 | 25.3 | |
| Current Liabilities | 619.7 | 162.4 | 651.3 | 1,229.9 | 373.8 | 384.5 | 216.3 | 200.4 | 100.1 | 105.9 | 99.6 | 92.9 | 56.7 | 61.9 | 71.1 | 75.7 |
| Current Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 57.4 | 63.7 | 58.1 | 60.9 | 82.1 | 95.9 | 100.2 | 112.2 | 112.7 | 108.3 | |
| Short-Term Debt | 0.0 | 1.8 | 0.0 | 2.7 | 3.5 | 418.3 | 462.5 | 413.7 | 413.6 | 455.2 | |
| Other Current Liabilities | 79.1 | 56.7 | 53.8 | 94.0 | 144.3 | 105.5 | 62.0 | 125.4 | 137.7 | 129.7 | |
| Current Liabilities | 136.5 | 127.1 | 111.9 | 162.4 | 229.9 | 619.7 | 630.2 | 651.3 | 664.0 | 693.2 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 447.0 | 673.4 | 446.5 | 448.5 | 809.4 | 841.0 | 798.4 | 784.5 | 13.5 | 248.1 | 253.0 | 251.0 | 62.0 | 58.3 | 54.1 | 30.2 | |
| Capital Leases | 11.5 | 12.4 | 13.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Def. Tax Liability | 34.8 | 41.7 | 0.0 | 71.8 | 94.9 | 53.2 | 65.9 | 67.5 | 12.5 | 0.0 | 0.0 | 0.0 | 1.4 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 1,127.2 | 906.9 | 1,173.9 | 1,783.6 | 1,340.0 | 1,436.2 | 1,240.8 | 1,218.5 | 157.9 | 373.9 | 383.6 | 392.1 | 137.5 | 122.1 | 130.1 | 126.8 |
| Long-Term Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 663.1 | 674.3 | 665.7 | 673.4 | 672.5 | 458.5 | 459.7 | 460.3 | 462.8 | 461.1 | |
| Capital Leases | 0.0 | 0.0 | 0.0 | 0.0 | 13.4 | 14.6 | 13.0 | 13.8 | 14.6 | 13.1 | |
| Def. Tax Liability | 36.3 | 46.5 | 60.4 | 48.9 | 0.0 | 0.0 | 34.8 | 58.9 | 52.4 | 57.9 | |
| Total Liabilities | 878.5 | 880.9 | 873.4 | 914.1 | 969.4 | 1,127.2 | 1,139.7 | 1,185.6 | 1,195.9 | 1,222.5 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Retained Earnings | -295.9 | -212.4 | -21.8 | 734.0 | 957.8 | 726.9 | 421.8 | 367.3 | 337.1 | 254.5 | 351.1 | 288.3 | 251.5 | 220.4 | 196.9 | 173.9 | |
| Comprehensive Income | -5.5 | -5.2 | -5.7 | 3.1 | -16.1 | -25.3 | -9.9 | -5.5 | -3.7 | -4.3 | -2.7 | -3.0 | -3.5 | -4.1 | -3.3 | -2.1 | |
| Total Common Equity | 386.3 | 482.8 | 649.3 | 1,383.0 | 1,619.0 | 1,447.0 | 1,088.5 | 1,010.9 | 912.3 | 596.2 | 660.0 | 553.2 | 489.6 | 441.4 | 414.2 | 369.5 |
| Total Common Equity | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
| Retained Earnings | -105.2 | -156.4 | -144.4 | -212.4 | -181.1 | -295.9 | -12.8 | -21.8 | 27.7 | 289.7 | |
| Comprehensive Income | -7.5 | -8.1 | -6.1 | -5.2 | -7.3 | -5.5 | -5.5 | -5.7 | -2.6 | -1.6 | |
| Total Common Equity | 582.5 | 536.2 | 552.7 | 482.8 | 508.4 | 386.3 | 663.9 | 649.3 | 697.2 | 956.3 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 876.8 | 676.1 | 860.2 | 1,405.8 | 841.0 | 874.8 | 811.3 | 794.6 | 13.5 | 268.1 | 253.0 | 251.0 | 62.0 | 62.8 | 59.5 | 47.4 | |
| Book Value | 386.3 | 482.8 | 649.3 | 1,383.0 | 1,619.0 | 1,447.0 | 1,088.5 | 1,010.9 | 912.3 | 596.2 | 660.0 | 553.2 | 489.2 | 442.1 | 416.7 | 373.6 |
| Other | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Book Value | 582.5 | 536.2 | 552.7 | 482.8 | 508.4 | 386.3 | 663.9 | 649.3 | 697.2 | 956.3 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -587.0 | 52.6 | -190.6 | -760.5 | -223.8 | 230.9 | 305.1 | 54.5 | 62.7 | 82.6 | 51.8 | 62.9 | 36.7 | 30.3 | 18.1 | 16.1 | 47.2 | |
| Depreciation & Amortization | 117.8 | 95.8 | 108.8 | 125.1 | 143.3 | 123.8 | 114.5 | 110.7 | 62.2 | 42.6 | 38.2 | 35.3 | 32.5 | 19.0 | 11.2 | 9.4 | 6.0 | |
| Stock-Based Compensation | 19.4 | 16.2 | 18.0 | 23.1 | 45.1 | 42.4 | 51.0 | 26.7 | 23.2 | 15.2 | 18.5 | 15.8 | 12.8 | 11.2 | 11.1 | 10.7 | 7.1 | |
| Change Working Capital | 220.1 | -22.4 | 88.7 | -70.3 | 0.5 | -156.4 | 8.8 | -39.9 | -119.1 | 53.7 | -45.5 | -65.9 | 13.5 | 24.1 | -12.8 | -46.5 | 21.9 | |
| Change In Accounts Receivable | 79.4 | 25.5 | -24.4 | -21.6 | 114.7 | -48.2 | 49.0 | -8.2 | -94.2 | -4.8 | -22.4 | -64.4 | 21.4 | 35.5 | -21.9 | -34.9 | 19.1 | |
| Change In Accounts Payable | -0.1 | -8.4 | -33.0 | 10.6 | -14.0 | -2.5 | 19.8 | 16.5 | -7.0 | 16.1 | -14.8 | 4.7 | -9.3 | -0.6 | 0.3 | 2.5 | 3.6 | |
| Change In Inventories | 6.9 | -30.3 | -24.5 | 0.6 | -51.9 | -44.0 | -83.2 | -16.7 | -1.9 | 6.1 | -9.0 | -11.3 | 4.2 | 0.5 | -0.5 | -1.9 | 0.8 | |
| Other Non-cash Items | 492.5 | 32.4 | 39.3 | 485.2 | 19.8 | 33.5 | 59.0 | 37.6 | 4.2 | 10.8 | -14.7 | -7.2 | 0.3 | -1.5 | 8.6 | 4.7 | 6.5 | |
| Cash from Operations | 77.0 | 0.0 | 0.0 | -206.3 | -34.1 | 321.1 | 536.0 | 188.0 | 41.8 | 208.1 | 53.5 | 44.5 | 112.3 | 97.0 | 39.6 | 14.6 | 99.5 |
| Cash Flow From Operating Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -54.6 | 51.2 | -12.0 | 68.0 | -31.3 | 114.8 | -283.1 | 9.0 | -49.5 | -263.4 | |
| Depreciation & Amortization | 23.5 | 23.4 | 23.5 | 25.4 | 26.0 | 26.4 | 28.5 | 27.9 | 30.5 | 29.1 | |
| Stock-Based Compensation | 5.3 | 4.8 | 4.6 | 1.5 | 0.0 | 2.3 | 5.5 | 5.9 | 4.0 | 4.0 | |
| Change Working Capital | 82.0 | -81.4 | 95.7 | -118.7 | -85.3 | 65.6 | 205.9 | -97.5 | 46.5 | 65.2 | |
| Change In Accounts Receivable | 51.9 | -71.6 | 118.5 | -73.3 | -77.1 | 82.3 | 20.4 | -50.0 | 36.9 | 72.1 | |
| Change In Accounts Payable | 11.4 | -4.0 | -10.4 | -5.4 | -10.2 | -23.0 | 2.6 | -2.4 | -7.1 | 6.8 | |
| Change In Inventories | 14.2 | -17.6 | -24.7 | -2.2 | 11.0 | -18.0 | -13.0 | -4.5 | 25.6 | -1.2 | |
| Other Non-cash Items | 20.0 | 9.9 | 8.5 | -6.0 | 11.1 | -62.7 | 90.9 | 4.3 | 5.8 | 218.6 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 32.1 | 60.0 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -39.4 | -13.8 | -22.9 | -51.6 | -115.8 | -225.0 | -141.0 | -86.9 | -72.1 | -54.8 | -76.3 | -44.8 | -30.7 | -42.0 | -53.8 | -54.0 | -22.1 | |
| Acquisitions | -270.2 | 0.0 | 0.0 | 270.2 | 0.0 | 0.0 | 0.0 | 0.0 | -827.7 | 0.0 | 0.0 | -0.7 | -179.4 | -25.9 | 0.0 | 0.0 | -17.9 | |
| Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -4.2 | -16.5 | |
| Sales of Investment | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.0 | 4.3 | 16.5 | |
| Other Investing Activities | 263.9 | 0.0 | 0.0 | -6.3 | -265.5 | 0.0 | -10.0 | -10.0 | 2.6 | -195.1 | 0.0 | 0.0 | 0.0 | 0.0 | 11.8 | 0.0 | 16.5 | |
| Cash from Investing | -45.7 | 0.0 | 0.0 | 212.3 | -381.3 | -225.0 | -151.0 | -96.9 | -897.2 | -249.9 | -76.3 | -45.5 | -210.1 | -67.9 | -40.1 | -54.0 | -23.5 |
| Cash Flow From Investing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -3.9 | -3.4 | -2.9 | -3.6 | -1.7 | -5.8 | -4.6 | -10.8 | -11.4 | -12.6 | |
| Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.0 | 0.0 | 0.0 | -270.2 | 0.0 | |
| Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Sales of Investment | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 270.2 | -6.3 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -11.4 | -18.9 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | -139.5 | 0.0 | 0.0 | -543.4 | -33.8 | -35.9 | -387.1 | -116.3 | -2.8 | -20.0 | 0.0 | 0.0 | -62.0 | -62.8 | -10.2 | -15.5 | -33.3 | |
| Debt Issued | 113.1 | 676.1 | -184.1 | -2.2 | 598.6 | 2.1 | 450.6 | 133.0 | 783.9 | -234.6 | 15.1 | 2.0 | 251.0 | 62.0 | 13.5 | 27.5 | 80.7 | |
| Issuance of Common Stock | 1.4 | 0.0 | 0.0 | 8.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.0 | 7.2 | |
| Repurchase of Common Stock | -0.8 | -24.9 | 0.0 | 0.0 | -82.1 | -106.0 | 0.0 | 0.0 | -0.1 | -33.1 | 0.0 | -0.1 | -0.2 | -0.2 | -5.9 | 0.0 | 61.2 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -46.2 | |
| Other Financing Activities | 7.4 | 0.0 | 0.0 | -0.7 | 597.1 | 0.9 | 456.6 | 80.4 | 791.6 | 1.7 | -18.6 | 33.5 | 261.1 | 71.6 | 14.4 | 19.7 | 1.7 | |
| Cash from Financing | -48.5 | 0.0 | 0.0 | -535.7 | 481.2 | -141.0 | 69.5 | -35.9 | 788.7 | -51.4 | -18.6 | 33.4 | 198.9 | 8.6 | -1.8 | 14.3 | -9.4 |
| Cash Flow From Financing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.1 | -42.9 | |
| Debt Issued | 663.1 | -13.0 | 10.4 | -10.4 | 0.1 | -200.8 | -45.4 | 44.7 | 468.0 | -446.7 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | |
| Repurchase of Common Stock | -9.1 | -8.9 | -6.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | -0.1 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.7 | -43.0 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -107.3 | 103.5 | -6.1 | -530.9 | 66.3 | -45.2 | 453.5 | 55.6 | -66.9 | -93.2 | -41.3 | 32.3 | 101.2 | 37.7 | -2.2 | -25.1 | 66.1 | |
| Closing Cash Balance | 71.0 | 209.1 | 105.6 | 111.7 | 642.6 | 576.3 | 621.5 | 168.0 | 112.4 | 178.3 | 271.5 | 312.8 | 280.5 | 179.3 | 141.7 | 143.9 | 169.0 |
| Cash position | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -40.1 | -21.8 | 118.2 | 47.2 | -50.8 | 85.4 | -8.0 | -32.7 | 23.9 | -90.5 | |
| Closing Cash Balance | 209.1 | 249.2 | 271.0 | 152.8 | 105.6 | 156.4 | 71.0 | 79.0 | 111.7 | -1.9 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 37.6 | 156.8 | 35.8 | -257.9 | -149.9 | 96.1 | 395.0 | 101.1 | -30.3 | 153.3 | -22.8 | -0.4 | 81.6 | 54.9 | -14.2 | -39.4 | 77.4 | |
| Real Free Cash Flow | 18.2 | 140.6 | 17.8 | -281.0 | -195.0 | 53.7 | 344.0 | 74.4 | -53.5 | 138.1 | -41.2 | -16.2 | 68.8 | 43.7 | -25.3 | -50.2 | 70.4 |
| Free Cash Flow | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 73.8 | -5.7 | 103.5 | -14.8 | -81.6 | 147.9 | 42.9 | -73.4 | 20.7 | 47.4 | |
| Real Free Cash Flow | 68.5 | -10.5 | 98.9 | -16.3 | -81.6 | 145.6 | 37.4 | -79.3 | 16.7 | 43.4 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | 8.8 | 34.8 | 2356.8 |
| P/S | 0.6 | 2.5 | 70.5 |
| P/B | 0.8 | 2 | 2015.4 |
| P/FCF | 3.3 | 12.6 | 7573.5 |
| Market cap | $0.6 | $0.8 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 45.4 % | 25.2 % | 0 % |
| Debt to Income | 1260.6 % | 664 % | 0 % |
| Debt to Free cash flow | 471.6 % | 309 % | 0 % |
| Interest expense percentage | 134.8 % | -22.3 % | 26.2 % |
| Current ratio | 5.8 | 4 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | 9 % | -2.8 % | 0 % |
| ROA | 3.6 % | 1.1 % | 0 % |
| CapEx to Revenue | 1.5 % | 10.3 % | 6 % |
| RaD to Revenue | 0 % | 24.5 % | 0 % |
| ROEM | 825,444.4 | 378796.1 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 57.8 % | 65.2 % | 74.8 % |
| Operating margin | 15 % | 7.9 % | 35 % |
| Net margin | 9.6 % | 2.5 % | 34.1 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 1.1 % | 0 % |
| Dividend payout percentage | 0 % | 33 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 56.5 mil | 46.5 mil |
| Employee count | 0.9 tis | 1.3 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
